• Multiple Myeloma

Dr. Freeman obtained her MD from the National University of Ireland, specialized in hematology at St Bartholomew’s in London, and obtained a master’s degree in Clinical Drug Development from Queen Mary University of London (QMUL). She also earned her PhD in immuno-oncology and therapeutics from the Barts Cancer Institute of QMUL under Professor John Gribben. She completed a fellowship in lymphoproliferative disorders and joins us from the British Columbia Cancer Agency in Vancouver, Canada, where she served as Assistant Professor and the Myeloma Lead. Dr. Freeman's clinical interests are focused on the treatment of patients with plasma cell neoplasms using autologous transplant and cellular immunotherapy. Her research interests are centered on optimizing outcomes for patients using this novel approach, identifying predictors of treatment failure or toxicity, new target discovery and clinical trial development, and identifying the best modalities for measuring disease burden and relapse. She is also interested in how to safely administer these highly effective and personalised cell therapies to all patients, including those with additional health concerns.